Evaluating the effect of Venlafaxine on irritable bowel syndrome

Evaluating the effect of Venlafaxine on gastrointestinal symptoms, depression, anxiety, stress and quality of life in patients with irritable bowel syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181118041691N1

Enrollment

Registered

2018-12-02

Start date

2016-11-02

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Control group: Treating with placebo (Pharmacy Faculty

Isfahan University of Medical Sciences

Iran) with similar shape, color and size of 37.5, 75 and 150 mg of Venlafaxine for three periods of two weeks, respectively. Intervention 2: Intervention group: Venlafaxine (Abidi

Iran)

37.5, 75 and 150 mg for three periods of two weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 65 years old presence of moderate to severe Irritable Bowel Syndrome symptoms having least educational level of writing and reading lacking of major psychological diseases (eg, depression, bipolar or psychotic mood disorders and presence of suicidal thoughts or plans) no history of administration of anti- depressant or anti-anxiolytic medications within two weeks prior to study initiation.

Exclusion criteria

Exclusion criteria: diagnosis of any other disease that inhibits patients to continue study pregnancy lactation patient's reluctance of using medications patient's reluctance of fulfilling questionnaires

Design outcomes

Primary

Measure	Time frame
Quality of life score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Quality of Life Questionnaire in Irritable Bowel Syndrome Patients (IBS-QOL).;Depression score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).;Anxiety score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).;Gastrointestinal symptoms. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: The Gastrointestinal Symptom Questionnaire.;Severity of Irritable Bowel Syndrome Symptoms. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: The Irritable Bowel Syndrome Severity Scoring System (IBSSS).;Stress score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).	—

Measure

Time frame

Quality of life score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Quality of Life Questionnaire in Irritable Bowel Syndrome Patients (IBS-QOL).;Depression score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).;Anxiety score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).;Gastrointestinal symptoms. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: The Gastrointestinal Symptom Questionnaire.;Severity of Irritable Bowel Syndrome Symptoms. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: The Irritable Bowel Syndrome Severity Scoring System (IBSSS).;Stress score. Timepoint: At baseline, within 2, 6 and 12 weeks after study and within 3 months after end of the study. Method of measurement: Depression, Anxiety and Stress Scale (DASS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPardis Adhamian

Esfahan University of Medical Sciences

adh276@yahoo.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026